8-K
Current Report
Viridian Therapeutics, Inc.\DE Filed Acc 0001590750-19-000063
Material agreement · Agreement ended · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.05 Costs associated with exit or disposal activities
- Item 5.02 Departure or appointment of directors or officers
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
From the SEC's structured data for this filing
Loading mgen-201912118k.htm…